Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02033382 · ClinicalTrials.gov registry record
Biomarkers in First Episode Schizophrenia
A clinical trial of Schizophrenia and Schizophreniform Disorder, sponsored by NYU Langone Health.
- Completed
- Registry status
- 165
- Enrollment target
- 1
- Study location
NCT02033382: Completed study of Schizophrenia and Schizophreniform Disorder, sponsored by NYU Langone Health.
NCT02033382 is a study of Schizophrenia and Schizophreniform Disorder that has completed, run by NYU Langone Health. The registered enrollment target is 165 participants, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02033382, a study of Schizophrenia and Schizophreniform Disorder, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after initiation of antipsychotic medication
Primary Outcome
Compare biomarkers for inflammation, BDNF, oxidative stress, glucocorticoids and folate/methylation status in medication-naïve schizophrenia/schizophreniform subjects and matched healthy controls to identify illness-related factors.
Conditions Studied
Study Locations (1)
New York
- Bellevue Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-12 |
What the finished NCT02033382 record still lists
NCT02033382 is an observational study that tracks outcomes without assigning an intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (24% lower).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.
NCT02033382 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02033382 about?
NCT02033382 is a clinical study titled "Biomarkers in First Episode Schizophrenia". This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after initiation of antipsychotic medication
What is the current status of trial NCT02033382?
This trial is currently completed. The enrollment target is 165 participants. The study started on 2012-07. Estimated completion is 2014-12.
What conditions does trial NCT02033382 study?
This clinical trial studies the following conditions: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type.
Who is sponsoring clinical trial NCT02033382?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02033382 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02033382's enrollment target sits among peer trials
165 98th of 315 higher than 218 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia